Relative Levels of BMS-986036 in Blood Plasma in Healthy, Overweight, and Obese Participants Following Subcutaneous Administration Via Auto-injector Versus Pre-filled Syringe

PHASE1CompletedINTERVENTIONAL

Enrollment

102

Participants

Timeline

Start Date

July 29, 2020

Primary Completion Date

June 11, 2021

Study Completion Date

June 11, 2021

Conditions

Healthy Participants

Interventions

DRUG

BMS-986036

Specified dose on specified days

Trial Locations (2)

ICON (LPRA) - Salt Lake, Salt Lake City

Anaheim Clinical Trials, Anaheim